ClinicalTrials.gg
Active, not recruitingNCT06113471Updated Mar 31, 2026

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)

A Phase 3 interventional study of Povorcitinib and Placebo in NonSegmental Vitiligo, sponsored by Incyte Corporation. Active, not recruiting at 86 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Vitiligo by Incyte Corporation — 2 open to participants now, 4 under way, 4 of them phase 3. Vitiligo · Incyte Corporation.

Enrollment
3rd of 12
450 · median 215
Started
2023
with 2 others
Phase 3
7 of 12
2 open now
Registered
9th of 12
by date

Among the 12 studies in Vitiligo by Incyte Corporation, this one is the 3rd largest by enrollment, is one of 3 that started in 2023, is one of 7 in phase 3, and was the 9th registered.

Vitiligo

343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.

Browse Vitiligo studies →

Open to participants now

2 of the 12 studies in Vitiligo by Incyte Corporation are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Vitiligo by Incyte Corporation, or all of them as a file.
02

Study summary

This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.

03

Conditions studied

  • NonSegmental Vitiligo

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥ 18 years.
  • Clinical diagnosis of nonsegmental vitiligo and meet the following:

    • T-BSA ≥ 5%
    • T-VASI score ≥ 4
    • F-BSA ≥ 0.5%
    • F-VASI score ≥ 0.5
  • Agreement to discontinue all agents and procedures used to treat vitiligo from screening through the final safety follow-up visit.
  • Willingness to avoid pregnancy or fathering children.

Exclusion criteria

Exclusion Criteria:

  • Other forms of vitiligo or skin depigmentation disorders.
  • abnormal TSH or free T4 at screening.
  • Use of laser or phototherapy within 8 weeks and dihydroxyacetone within 4 weeks prior to Day 1.
  • Current or past use of the depigmenting agent monobenzyl ether of hydroquinone including Benoquin®.
  • History of melanocyte-keratinocyte transplantation procedure or other surgical treatment for vitiligo.
  • Spontaneous and significant repigmentation within 6 months prior to screening.
  • Women who are pregnant, considering pregnancy, or breast feeding.
  • Medical history including thrombocytopenia, coagulopathy or dysfunction; venous and arterial thrombosis, deep vein thrombosis, pulmonary embolism, stroke, moderate to severe heart failure, cerebrovascular accident, myocardial infarction, or other significant cardiovascular diseases; Q-wave interval abnormalities; disseminated herpes zoster or recurrent dermatomal herpes zoster; disseminated herpes simplex; chronic/recurrent infections; .
  • Evidence of infection with TB, , or .
  • History of failure to JAK inhibitor treatment of any inflammatory disease.
  • Laboratory values outside of the protocol-defined ranges.

Other protocol-defined Inclusion/Exclusion Criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
450 participants (actual)

Study arms

  • Experimental
    Experimental: Povorcitinib Dose A

    Participants will receive Povorcitinib Dose A for 52 weeks, followed by Povorcitinib Dose A for 52 weeks.

    Drug: Povorcitinib

  • Placebo comparator
    Placebo

    Participants will receive Placebo for 52 weeks, followed by Povorcitinib Dose A for 52 weeks.

    Drug: Placebo

Interventions

  • Oral, Tablet

    Also known as: INCB054707

  • DrugPlacebo

    Oral, Tablet

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Achieving a ≥ 75% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI75)

    ≥75% improvement in facial Vitiligo Area Scoring Index.

    Time frame: Week 52

Secondary outcomes

  1. Percentage change from Baseline in Total Body Vitiligo Area Scoring Index (T-VASI)

    Percentage change from Baseline in total body Vitiligo Area Scoring Index.

    Time frame: Week 52

  2. Proportion of Participants Achieving a ≥ 50% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI50)

    ≥50% improvement in total body Vitiligo Area Scoring Index.

    Time frame: Week 52

  3. Proportion of Participants Achieving a ≥ 75% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI75)

    ≥75% improvement in total body Vitiligo Area Scoring Index.

    Time frame: Week 52

  4. Proportion of participants achieving a Vitiligo Noticeability Scale Score (VNS) of 4 or 5

    VNS is a participant reported outcome measure on a scale of 1-5, 1- more noticeable, 4 - a lot less noticeable, and 5- no longer noticeable.

    Time frame: Week 52 and Week 104

  5. Number of participants with Treatment-emergent Adverse Events (TEAEs)

    Defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug.

    Time frame: Up to Week 104 and 30 days

  6. Proportion of Participants Achieving Facial Vitiligo Area Scoring Index (F-VASI50)

    ≥50% improvement in facial Vitiligo Area Scoring Index.

    Time frame: Week 52 and Week 104

  7. Proportion of Participants Achieving Facial Vitiligo Area Scoring Index (F-VASI75)

    ≥75% improvement in facial Vitiligo Area Scoring Index.

    Time frame: Week 104

  8. Proportion of Participants Achieving Facial Vitiligo Area Scoring Index (F-VAS190)

    ≥90% improvement in facial Vitiligo Area Scoring Index.

    Time frame: Week 52 and Week 104

  9. Proportion of Participants Achieving Total Body Vitiligo Area Scoring Index (T-VASI50)

    ≥50% improvement in total body Vitiligo Area Scoring Index.

    Time frame: Week 104

  10. Proportion of Participants Achieving Total Body Vitiligo Area Scoring Index (T-VASI75)

    ≥75% improvement in total body Vitiligo Area Scoring Index.

    Time frame: Week 104

  11. Proportion of Participants Achieving Total Body Vitiligo Area Scoring Index (T-VASI90)

    ≥90% improvement in total body Vitiligo Area Scoring Index.

    Time frame: Week 52 and Week 104

  12. Proportion of participants achieving an Facial Static Investigator Global Assessment (FSIGA) of 0 or 1

    Global score of vitiligo severity for the face. Scores range from 0 (clear) to 5 (severe vitiligo).

    Time frame: Week 52 and Week 104

  13. Proportion of participants in each Facial Static Investigator Global Assessment (FSIGA) category

    Global score of vitiligo severity for the face. Scores range from 0 (clear) to 5 (severe vitiligo).

    Time frame: Week 52 and Week 104

  14. Proportion of participants achieving a Static Investigator Global Assessment (SIGA) of 0 (clear) or 1 (almost clear)

    Global score of vitiligo severity for the entire body. Scores range from 0 (clear) to 5 (severe vitiligo).

    Time frame: Week 52 and Week 104

  15. Proportion of participants in each Static Investigator Global Assessment (SIGA) category

    Global score of vitiligo severity for the entire body. Scores range from 0 (clear) to 5 (severe vitiligo).

    Time frame: Week 52 and Week 104

  16. Proportion of participants who report Facial Patient Global Impression of Change-Vitiligo (F-PaGIC-V) of 1 or 2

    F-PaGIC-V is an assessment of improvement of vitiligo on the face by the participant. It is a 7-point scale ((1) Very much improved, (2) Much improved, (3) Minimally improved, (4) No change, (5) Minimally worse, (6) Much worse, or (7) Very much worse).

    Time frame: Week 52 and Week 104

  17. Proportion of participants in each Facial Patient Global Impression of Change-Vitiligo (F-PaGIC-V) category

    F-PaGIC-V is an assessment of improvement of vitiligo on the face by the participant. It is a 7-point scale ((1) Very much improved, (2) Much improved, (3) Minimally improved, (4) No change, (5) Minimally worse, (6) Much worse, or (7) Very much worse).

    Time frame: Week 52 and Week 104

  18. Proportion of participants who report Total Body Patient Global Impression of Change-Vitiligo (T-PaGIC-V) of 1 or 2

    T-PaGIC-V is an assessment of improvement of vitiligo on the total body by the participant. It is a 7-point scale ((1) Very much improved, (2) Much improved, (3) Minimally improved, (4) No change, (5) Minimally worse, (6) Much worse, or (7) Very much worse).

    Time frame: Week 52 and Week 104

  19. Proportion of participants in each Total Body Patient Global Impression of Change-Vitiligo (T-PaGIC-V) category

    T-PaGIC-V is an assessment of improvement of vitiligo on the total body by the participant. It is a 7-point scale ((1) Very much improved, (2) Much improved, (3) Minimally improved, (4) No change, (5) Minimally worse, (6) Much worse, or (7) Very much worse).

    Time frame: Week 52 and Week 104

  20. Proportion of participants in each category for the color-matching question

    Participants will answer how well the color of the treated skin matches the normal skin on a scale of 1-5, 1 being excellent to 5 being very poor.

    Time frame: Week 52 and Week 104

  21. Change from baseline in the Vitiligo-Specific Quality of Life (VitiQoL)

    VitiQoL is a 15-item QoL assessment that asks participants to rate various aspects of their condition during the past month using a 7-point scale ("Not at all" to "All of the time").

    Time frame: Week 52 and Week 104

  22. Change from baseline in the Hospital Anxiety and Depression Scale (HADS) subscales

    HADS is a 14-item questionnaire that assesses the levels of anxiety and depression that a participant is currently experiencing. There are 7 questions each for measuring anxiety and for measuring depression, with 4 possible responses to each question (responses are scored as 0, 1, 2, or 3).

    Time frame: Week 52 and Week 104

07

Study locations

86 sites
08

References and documents

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Mar 2026, 27 months.

Of 18 phase 3 interventional studies under Vitiligo, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 44. This study's 27 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2023
First posted
Nov 2, 2023
StartActual
Nov 27, 2023
Primary completionActual
Mar 17, 2026
CompletionEst.
Mar 16, 2027
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06113471
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Nov 2, 2023
Start date
Nov 27, 2023
Primary completion
Mar 17, 2026
Completion
Mar 16, 2027 (estimated)
Last update
Mar 31, 2026

Study contacts

Incyte Medical Monitor
study director · Incyte Corporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Povorcitinib

Start the discussion